Home»Smart Health»EIB supports NewIcon’s development of innovative healthcare automation solutions

EIB supports NewIcon’s development of innovative healthcare automation solutions

0
Shares
Linkedin Pinterest Google+

The European Investment Bank (EIB) has provided a EUR 8 million loan to NewIcon for its development and innovation activities in the field of medicine logistics. The company’s new automation solutions will facilitate the work of nursing staff at each stage of the medicine supply process in pharmacies and hospital wards.

NewIcon is a fast-growing medical technology company that manufactures automation solutions for hospitals and pharmacies with technology that relies on robotics and the Internet of Things. The company will allocate the funds from the EIB loan to the development and production of total pharmacy automation solutions. More precisely, the company will further develop its range of storage retrieval robots for pharmacies and automated dispensing cabinets for hospital wards. The EIB funds will also support the development of intravenous compounding robots and novel medication management software. All this addresses unmet and growing needs within the healthcare industry for increased efficiency and safety in medication management.

This transaction is supported by the new generation of financial instruments for innovative growth companies “InnovFin – EU Finance for Innovators”, with the financial backing of the European Union under Horizon 2020. “InnovFin MidCap Growth Finance” is specifically dedicated to improving access to risk finance for the research and innovation projects of midcaps and SMEs. Earlier beneficiaries of such EIB backing in Finland were the innovative companies Rovio and Kiosked.

Jan Vapaavuori, EIB Vice-President responsible for operations in Finland, said: “Midcap companies have a key role to play in competitiveness, job creation and growth in Europe. “InnovFin – EU Finance for Innovators” joint financial instruments aim to support midcap companies that consistently prove to be particularly strong in innovation. NewIcon, as a fast-growing and innovative company with solid growth potential, is an ideal candidate for this facility.”

Ossi Parviainen, NewIcon’s CEO, added: “Our solutions provide an answer to the global megatrend in health care, i.e. ageing, due to which pharmaceuticals are consumed at an increasing rate and nursing staff resources are under pressure. Automation is the remedy for ensuring patient safety. We have invested in product development and are beginning to see the results. We have plenty of new aces up our sleeves that we can pull out to challenge our global competitors. We are honoured to be included among such innovative companies as the mobile entertainment services company Rovio and the advertising technology company Kiosked. It is great to be the third Finnish company, and particularly a health technology company from Kuopio, to meet the EIB’s strict financing criteria for the InnovFin MidCap Growth Finance programme.”

The EIB loan will enable NewIcon to scale up operations quickly in a fast-moving market and help it maintain its competitive edge by providing finance to accelerate the company’s development and innovation activities. NewIcon currently employs more than 50 people and the number is expected to quadruple within the next three years. Staff will also be hired at international branches, the first of which was established in the United Kingdom in early 2016. Next, the plan is to establish a branch in each Nordic country.

EIB Vice-President Vapaavuori commented: “We are pleased to be partnering with NewIcon in this breakthrough operation as this will support the firm’s evolution from a local champion to a globally active industrial company. Supporting a successful European health technology enterprise will enable the EU bank to enhance Europe’s position as a major technology supplier and promote skilled employment opportunities.”

NewIcon’s CEO Parviainen said: “Our growth objective is to achieve a tenfold increase in revenue and to attain a one percent market share in global medicine supply automation by the year 2020. This constitutes a big slice for us in a growing market whose value is expected to reach 70 billion euros in the next few years, according to our studies. This means that we will also allocate funds from the EIB to investments in international growth to secure our access to new market areas.”

Previous post

Accela and DocuSign to Digitize Government with Electronic Signatures

Next post

Delhi municipal corporations switch to LED lights to cut costs

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *